Doctors have substantial evidence documenting the use of cannabinoids to target chronic pain and neuropathy, but in most cases, according to Dr. Grossman from the Cambridge (Mass.) Health Alliance, cannabinoids are compared to placebo as opposed to other pain medications that patients have access to.
One systematic review published in the Journal of the American Medical Association (JAMA) analyzed 79 studies and involved 6,462 participants. The review found cannabinoids offered a greater average number of patients complete nausea and vomiting response (47% in comparison to 20%), pain reduction (37% as opposed to 31%), and a greater average reduction in patients' pain assessment when rated on the numerical scale and the Ashworth spasticity scale. Another study meta-analysis which can be found in the Journal of Pain looked at the effects of inhaled cannabis sativa versus a placebo when targeting chronic painful neuropathy. Researchers found patients who were offered cannabis sativa were 3.2 times more likely to reach a 30% or greater reduction in pain than those who were not.
This information has been provided by the JAMA Network and the Journal of Pain and approved by our Chief Medical Officer.